This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cody, H. S. Articles by Tan, L. K. Search for Related Content PubMed PubMed Citation Articles by Cody, H. S., III Articles by Tan, L. K.

Redefining Prognosis in Node-Negative Breast Cancer: Can Sentinel Lymph Node Biopsy Raise the Threshold for Systemic Adjuvant Therapy?

From The Breast Service, Department of Surgery (HSC, PIB) and Department of Pathology (LKT), Memorial Sloan-Kettering Cancer Center, New York, New York.

Correspondence: Address correspondence and reprint requests to: Hiram S. Cody III, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; Fax: 212-794-5812; E-mail: codyh{at}mskcc.org

ABSTRACT

Sentinel lymph node (SLN) biopsy is a new standard of care for axillary node staging in breast cancer, which for the first time allows enhanced pathologic analysis on a routine basis. Although a number of retrospective studies, including our own series with 20-year follow-up, suggest that axillary nodal micrometastases found in this manner are prognostically significant, prospective trials now under way promise a definitive answer to this controversial subject. Enhanced pathology using serial sections and immunohistochemical staining identifies a high-risk minority of conventionally node-negative patients who are converted to node-positive and thereby become candidates for systemic adjuvant chemotherapy. The developmental phase of SLN biopsy, now drawing to a close, has focused on the identification of this node-positive group. Enhanced pathology also identifies a majority of patients who are truly node-negative and whose expectation of long-term survival exceeds that of historic norms for node-negative breast cancer. The next era of SLN biopsy should focus on the characterization of this group. SLN biopsy in breast cancer has already extended the historic trend toward surgical conservatism. By defining more precisely a low-risk cohort of patients, SLN biopsy has the potential to initiate a trend toward medical conservatism as well.

Key Words: Immunohistochemical staining • Node-negative breast cancer • Sentinel lymph node biopsy • Systemic adjuvant therapy

This article has been cited by other articles:

				K. A. Vanderveen, R. Ramsamooj, and R. J. Bold A Prospective, Blinded Trial of Touch Prep Analysis versus Frozen Section for Intraoperative Evaluation of Sentinel Lymph Nodes in Breast Cancer Ann. Surg. Oncol., July 1, 2008; 15(7): 2006 - 2011. [Abstract] [Full Text] [PDF]

				D. M. Iddings, E. A. Koda, S. S. Grewal, R. Parker, S. Saha, and A. Bilchik Association of Angiogenesis Markers With Lymph Node Metastasis in Early Colorectal Cancer Arch Surg, August 1, 2007; 142(8): 738 - 745. [Abstract] [Full Text] [PDF]

				D. P. Cronin-Fenton, L. A. Ries, L. X. Clegg, and B. K. Edwards Rising Incidence Rates of Breast Carcinoma With Micrometastatic Lymph Node Involvement J Natl Cancer Inst, July 4, 2007; 99(13): 1044 - 1049. [Abstract] [Full Text] [PDF]

				K. A. Vanderveen, P. D. Schneider, V. P. Khatri, J. E. Goodnight, and R. J. Bold Upstaging and Improved Survival of Early Breast Cancer Patients after Implementation of Sentinel Node Biopsy for Axillary Staging Ann. Surg. Oncol., November 1, 2006; 13(11): 1450 - 1456. [Abstract] [Full Text] [PDF]